The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cellsJohannes Kraus, Christoph Driessen|Cancer Chemotherapy and Pharmacology|2015Cited by 21